Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Tambotatug pelitecan leads to better clinical outcomes than topotecan among patients with relapsed SCLC after platinum-based therapy
Дата публикации: 28-09-2026 07:00:00

Findings from the TAISHAN-302 study

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China017.113-09-2026
2Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer06.401-09-2026
3Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer014.3501-09-2026
4No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC016.4124-09-2026
5GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan014.9123-03-2026
6EMA recommends granting a marketing authorisation for relacorilant09.2502-10-2026
7FLOT vs CROSS in Esophageal Adenocarcinoma06.0501-09-2026
8EMA recommends extension of indications for pirtobrutinib08.8625-09-2026
9Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection01008-10-2026
10GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA 016.4710-12-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.55. Источник: www.esmo.org.